Dana-Farber Cancer Institute

This is your central portal for breaking news, the latest research and important updates from Dana-Farber Cancer Institute. Bookmark this page and check back often for updates.

In the Journals

Stress ‘primary driver’ for fatigue in patients with SLE

September 12, 2019
Although depression and stress are both predictors of fatigue among patients with systemic lupus erythematosus at 1 year, stress is the…
In the Journals

Exercise linked to longer PFS, fewer treatment-related toxicities in metastatic colorectal cancer

August 21, 2019
Patients with metastatic colorectal cancer who exercised regularly achieved longer PFS than those who did not, according to results of a companion…

American Society for Radiation Oncology members receive fellow designation

August 8, 2019
American Society for Radiation Oncology designated 26 members to receive ASTRO fellow designation. The honorees will be recognized during the…

The University of Texas MD Anderson Cancer Center ranked best cancer hospital in nation

July 30, 2019
The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country. MD Anderson tops U.S
Meeting News

HemOnc Today honors Next Gen Innovators

HemOnc Today, July 25, 2019
HemOnc Today held a reception at ASCO Annual Meeting to honor its third class of Next Gen Innovators. The publication’s 111 Next Gen…
Point/Counter

Should lenvatinib be used as first-line therapy for slowly progressing radioiodine-refractory thyroid carcinoma?

HemOnc Today, July 10, 2019
POINT Lenvatinib is my preference as a first-line therapy when patients need treatment beyond levothyroxine and thyroid-stimulating hormone suppression.
Meeting NewsVideo

VIDEO: Tumor size, node status, age affect risk for breast cancer mortality

July 10, 2019
CHICAGO — At the ASCO Annual Meeting, Jose Pablo Leone, MD, medical oncologist at Dana-Farber Cancer Institute, spoke with HemOnc Today
Meeting NewsVideo

VIDEO: Eribulin plus pembrolizumab shows no clinical benefit in breast cancer subtype

July 2, 2019
CHICAGO — The addition of pembrolizumab to eribulin demonstrated no significant improvements in terms of PFS, OS or objective response rate…
In the Journals

High cardiac radiation dose may increase mortality odds in patients with lung cancer

July 2, 2019
Among patients with non-small cell lung cancer, a higher cardiac radiation dose may lead to elevated risk for major adverse cardiac events and…

OncoSec, Dana-Farber strike exclusive rights agreement for CAR T-cell technology

June 30, 2019
OncoSec Medical has announced a collaborative agreement with Dana-Farber Cancer Institute for the development of chimeric antigen receptor T-cell…
Feature

Dana-Farber clinic to focus on blood cancer precursor conditions

June 28, 2019
Dana-Farber Cancer Institute opened a new clinic designed to improve clinical care and monitoring for individuals with precursor conditions that can…
In the Journals

FDA-approved cancer drugs take more than 6 years to reach children

June 25, 2019
FDA-approved oncology agents took a median 6.5 years to proceed from first-in-human to first-in-child clinical trials, according to research…
Cover Story

Despite promising new regimens, search for cure is ‘highest priority’ in advanced renal cell carcinoma

HemOnc Today, June 25, 2019
With approximately 73,820 diagnoses and 14,770 deaths expected this year in the U.S., renal cell carcinoma remains a cancer in need of new treatment…
In the Journals

Walking speed, grip strength predict outcomes among older patients with blood cancers

June 21, 2019
Walking speed appeared to be an important predictor of survival and hospital utilization among older patients with hematologic malignancies…
Meeting NewsVideo

VIDEO: Talazoparib improves PFS in patients with BRCA mutations

June 20, 2019
CHICAGO — At the ASCO Annual Meeting, Jose Pablo Leone, MD, medical oncologist at Dana-Farber Cancer Institute, spoke with HemOnc Today

Dana-Farber/Boston Children’s named nation’s best hospital for pediatric cancer

June 18, 2019
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center has reclaimed its distinction as the No. 1 children’s hospital for cancer…
Meeting NewsPerspective

Triplet therapy confers benefit among certain patients with advanced breast cancer

June 13, 2019
CHICAGO — The combination of ribociclib, everolimus and exemestane conferred clinical benefit and appeared tolerable among patients with…
Meeting NewsPerspective

Enzalutamide improves OS for metastatic hormone-sensitive prostate cancer

June 10, 2019
CHICAGO — Enzalutamide used in combination with standard therapy significantly improved OS compared with other nonsteroidal antiandrogen drugs…
Meeting News

Conquer Cancer Foundation presents Merit Awards at ASCO

June 6, 2019
CHICAGO — The Conquer Cancer Foundation of ASCO presented ASCO Annual Meeting Merit Awards to more than 100 oncology professionals. The awards…
Meeting NewsPerspective

Isatuximab regimen extends PFS in relapsed, refractory multiple myeloma

June 5, 2019
CHICAGO — The addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved PFS and overall response rate among…